



Curriculum Vitae

Personal information **Darius Matusevicius**

Work experience

1. Employer: Medical Products Agency
 - Start date: 2012
 - End date:
 - Position: Senior clinical assessor
 - Activities: COMP delegate, Member of CNSWP
 - Country: Sweden
2. Employer: AstraZeneca
 - Start date: 2001
 - End date: 2013
 - Position: Team Leader/Senior Clinical Research Physician
 - Activities: Biochemical biomarker for neurological diseases (MS, AD, PD) team leader Study physician in phase I and II Clinical studies Clinical Development program development for Products for PD treatment
 - Country: Sweden
3. Employer: Neurological Clinic, Kaunas Academical Clinic
 - Start date: 1992
 - End date: 1998
 - Position: Neurologist
 - Activities:
 - Country: Lithuania

Education and training

1. Subject: Kaunas Medical Academy
 - Start date: 1984
 - End date: 1990
 - Qualification: Physician
 - Organisation:
 - Country: Lithuania
2. Subject: Kaunas Medical Academy
 - Start date: 1990
 - End date: 1992
 - Qualification: Neurologist
 - Organisation:
 - Country: Lithuania
3. Subject: Karolinska Institute
 - Start date: 1995
 - End date: 1997
 - Qualification: PhD in Neurology
 - Organisation: Neuroimmunology Multiple Sclerosis Myasthenia Gravis
 - Country: Sweden
4. Subject: Karolinska Institute
 - Start date: 2008
 - End date: 2009
 - Qualification: Diploma in Pharmaceutical Medicine
 - Organisation: Drugs in Society Drugs discovery/ and early development Pharmacokinetics/Pharmacodynamics and special populations Applied Statistics in Drug Development Planning a Clinical trial Evaluation of Clinical trials & Risk/Benefit Pharmacoepidemiology Quality of Life & Health Economy Outcome Research Marketing and Drug information
 - Country: Sweden

Additional information

Publications

1. Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko_Vargad G, Végvári A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M and Olsson T. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. Journal of Proteomics 2010; 73: 1117_32. 2. Filion LG, Matusevicius D, Graziani_Bowering GM, Kumar A, Freedman MS. Monocyte_derived IL12, CD86 (B7_2) and CD40L expression in relapsing and progressive multiple sclerosis. Clinical Immunology 2003; 106(2): 127_38. 3. Filion LG, Graziani_Bowering G, Matusevicius D, Freedman MS. Monocyte_derived cytokines in multiple sclerosis. Clinical & Experimental Immunology 2003; 131(2): 324_34. 4. Matusevicius D and Freedman MS. Immune system, overview. Encyclopedia of the Neurological Sciences. 2003:633_639. 5. Murzenok PP, Matusevicius D, Freedman MS. Gamma/delta T cells in multiple sclerosis: chemokine and chemokine receptor expression. Clinical Immunology 2002; 103(3 Pt 1): 309_16. 6. Teleshova N, Matusevicius D, Kivisakk P, Mustafa M, Pirskanen R, Link H. Altered expression of costimulatory molecules in myasthenia gravis. Muscle & Nerve 2002; 23(6): 946_53. 7. Ozenci V, Rinaldi L, Teleshova N, Matusevicius D, Kivisakk P and Link H. Metalloproteinases and their inhibitors in multiple sclerosis. J Autoimmun 1999; 12:297_303. 8. Matusevicius D, Kivisakk P, He B, Navikas V, Fredrikson S and Link H. IL_17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Multiple Sclerosis 1999; 5:101_104. 9. Kivisakk P, Stawiarz L, Matusevicius D, Fredrikson S, Söderström M, Hindmarsh T and Link H. High numbers of perforin mRNA expressing CSF cells in multiple sclerosis patients with gadolinium_enhancing brain MRI lesions. Acta Neurol Scand 1999; 100:18_24. 10. Pelidou S.H., Kostulas N., Matusevicius D., Kivisakk P.,

Kostulas V. and Link H. High levels of IL_10 secreting cells are present in blood in cerebrovascular diseases. Eur J Neurol 1999; 6:437_442. 11. Fu_Dong Shi, Li Hu, He Bing, Matusevicius D, Link H. and Ljungren H_G. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur J Immunol 1998; 11:3587_3693. 12. Kivisäkk P, Teleshova N, Özenci V, Huang Y, Matusevicius D, Pirskanen R, Söderström M, Fredrikson S and Link H. No evidence for elevated numbers of mononuclear cells expressing MCP_1 and RANTES mRNA in blood and CSF in multiple sclerosis. J Neuroimmunol 1998; 91:108_112. 13. Kostulas N, Kivisäkk P, Yumin H, Matusevicius D, Kostulas V and Link H. Ischemic stroke is associated with the systemic increase of blood mononuclear cells expressing IL_8 mRNA. Stroke 1998; 29:462_466. 14. Matusevicius D, Kivisäkk P, Navikas V, Tian W_Z, Söderström M, Fredrikson S and Link H. Effects of IFN_γ1b (Betaferon) treatment on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM_1 in multiple sclerosis. Eur J Neurol 1998; 5:265_275. 15. Matusevicius D, Navikas V, Kivisäkk P, Söderström M, Höjeberg B, Ljungdahl Å, Fredrikson S and Link H. IL_12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis. Scand J Immunol 1998; 47:582_590. 16. Tian W_Z, Navikas V, Matusevicius D, Söderström M, Fredrikson S, Link H. In vitro effects of Linomide (roquinimex) affects the balance between pro_ and anti_inflammatory cytokines in multiple sclerosis. Acta Neurol Scand 1998; 98:94_101. 17. Kivisäkk P, Matusevicius D, He B, Matell R, Söderström M, Fredrikson S, Link H. Interleukin_15 mRNA expression is upregulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. Clin Exp Immunol 1998; 111:193_197. 18. Kivisäkk P, Tian W_Z, Matusevicius D, Link H, Söderström M. Optic neuritis and cytokines: no relation to MRI abnormalities and oligoclonal bands. Neurology 1998; 50:217_223. 19. Navikas V, Matusevicius D, Söderström M, Pirskanen R, Fredrikson S, Link H. The phosphodiesterase IV inhibitor rolipram selectively suppresses production of proinflammatory cytokines in blood mononuclear cells from patients with multiple sclerosis. Clin Neuropharmacol 1998; 21:236_244. 20. Kivisäkk P, Alm G, Tian W_Z, Matusevicius D, Fredrikson S, Link H. Neutralising and binding anti_interferon_γ1b (IFN_γ1b) antibodies during IFN_γ1b treatment of multiple sclerosis. Multiple Sclerosis 1997; 3:184_190. 21. Navikas V, Martin C, Matusevicius D, Söderström M, Fredrikson S, Link H. Soluble CD30 levels in plasma and cerebrospinal fluid in multiple sclerosis, HIV infection and other neurological disease. Acta Neurol Scand 1997; 95:99_102. 22. Matusevicius D, Kivisäkk P, Navikas V, Xiao B_G, Söderström M, Olsson T, Pirskanen R, Fredrikson S and Link H. Autoantigen_induced IL_13 mRNA expression is increased in blood mononuclear cells in myasthenia gravis and multiple sclerosis. Eur J Neurol 1997; 4:468_475. 23. Matusevicius D, Navikas V, Palasik W, Pirskanen R, Fredrikson S and Link H. TNF_α, lymphotoxin, IL_6, IL_10, IL_12 and perforin mRNA expression in mononuclear cells in response to AChR is augmented in myasthenia gravis. J Neuroimmunol 1996; 71:191_198. 24. Navikas V, Matusevicius D, Söderström M, Fredrikson S, Kivisäkk P, Ljungdahl Å, Höjeberg B and Link H. Increased interleukin_6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J Neuroimmunol 1996; 64:63_69. 25. Matusevicius D, Navikas V, Söderström M, Xiao B_G, Haglind M, Fredrikson S and Link H. Multiple sclerosis: the proinflammatory cytokines lymphotoxin_α and tumor necrosis factor_α are upregulated in cerebrospinal fluid mononuclear cells. J Neuroimmunol 1996; 66:115_123.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)